Abstract:Hepatitis C virus (HCV) is a small (approximately 55 to 65 nm), spherical, enveloped, hepatotropic RNA virus that causes acute and chronic hepatitis in humans. Persistent virus infection with HCV often leads to cirrhosis and hepatocellular carcinoma (HCC). At present there is neither a selective antiviral therapy nor a preventive vaccine. The only available treatment option is a long-acting pegylated-interferon-alpha, given in combination with nucleoside analog ribavirin, which is not very effective. Molecular studies of HCV began with the successful cloning of its genome in 1989. For many years, research to develop therapeutics was stalled by the inability to grow virus in tissue culture. A major milestone was achieved with the recent development of a robust cell culture system for HCV propagation. HCV proteins assemble and form replication complexes on modified host membranes, called as membranous webs. Even though HCV is detected and targeted by host immune mechanisms, it establishes and maintains a life-long persistent infection. HCV has evolved multiple strategies to survive and persist in hostile cellular environments; and the viral population is known to rapidly change during the course of a natural infection thereby escaping immune surveillance. Rapid mutations also help virus to survive by selecting for the variants which are resistant to antiviral drugs. Although precise mechanisms regulating HCV entry into hepatic cells via receptors remain unknown, HCV also has the capability of direct cell-to-cell transmission. The extremely complex and incompletely understood nature of the HCV lifecycle has complicated the discovery of new therapies. A complete understanding of the functional roles played by the HCV proteins during HCV lifecycle is vital for developing a successful cure. This review deals with current status of efforts in addressing these daunting tasks and challenges in developing therapeutics against chronic and rapidly changing hepatitis C virus.

Hepatitis C: The Story of a Long Journey through First, Second, and Third Generation NS3/4A Peptidomimetic Inhibitors. What Did We Learn?

Recent Advance in Antiviral Drugs for Hepatitis C.

Clinical efficacy and safety of ravidavir-based antiretroviral regimen in treatment of patients with chronic hepatitis C

From non-A, non-B hepatitis to hepatitis C virus cure

A Synopsis of Hepatitis C Virus Treatments and Future Perspectives

Understanding the hepatitis C virus life cycle paves the way for highly effective therapies

Resistance Mutations Against HCV Protease Inhibitors and Antiviral Drug Design.

Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy

Breakthroughs in hepatitis C research: from discovery to cure

Viral hepatitis: Innovations and expectations

From Discovery to Cure, A Great Journey of the Hepatitis C Virus Study

New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges

Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection

An Insight into Hepatitis C Virus: In Search of Promising Drug Targets

Update on Hepatitis C Vaccine: Results and Challenges

The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment

Hepatitis C virus: A global view

Recent progress in direct-acting antiviral agents for chronic hepatitis C

Recent Progress and Future Prospects of Direct-Acting Antiviral Agents for Chronic Hepatitis C

Elimination of HCV Infection: Recent Epidemiological Findings, Barriers, and Strategies for the Coming Years

Hepatitis C virus: molecular biology & current therapeutic options